162 related articles for article (PubMed ID: 11516864)
1. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment.
Girinsky T; Guillot-Vals D; Koscielny S; Cosset JM; Ganem G; Carde P; Monhonval M; Pereira R; Bosq J; Ribrag V; Vantelon JM; Munck JN
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):148-55. PubMed ID: 11516864
[TBL] [Abstract][Full Text] [Related]
2. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):17-22. PubMed ID: 11163493
[TBL] [Abstract][Full Text] [Related]
3. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas.
Girinsky T; Lapusan S; Ribrag V; Koscielny S; Ferme C; Carde P
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):476-9. PubMed ID: 15667970
[TBL] [Abstract][Full Text] [Related]
6. [Radiotherapy of primary extranodal non-Hodgkin's lymphoma of the head and neck region. Results of a prospective multicenter study. Study Group NHL: early studies].
Hoederath A; Sack H; Stuschke M; Lampka E
Strahlenther Onkol; 1996 Jul; 172(7):356-66; discussion 367-8. PubMed ID: 8693402
[TBL] [Abstract][Full Text] [Related]
7. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma.
Kamath SS; Marcus RB; Lynch JW; Mendenhall NP
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):563-8. PubMed ID: 10348285
[TBL] [Abstract][Full Text] [Related]
8. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma.
Chan EK; Fung S; Gospodarowicz M; Hodgson D; Wells W; Sun A; Pintile M; Tsang RW
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e781-6. PubMed ID: 21167657
[TBL] [Abstract][Full Text] [Related]
9. Treatment results of tonsillar lymphoma: a 10-year experience.
Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy.
Smith K; Byer G; Morris CG; Kirwan JM; Lightsey J; Mendenhall NP; Hoppe BS; Lynch J; Olivier K
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1122-7. PubMed ID: 21570217
[TBL] [Abstract][Full Text] [Related]
11. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Tseng YD; Chen YH; Catalano PJ; Ng A
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):223-31. PubMed ID: 25835625
[TBL] [Abstract][Full Text] [Related]
12. Low-dose radiotherapy in indolent lymphoma.
Rossier C; Schick U; Miralbell R; Mirimanoff RO; Weber DC; Ozsahin M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e1-6. PubMed ID: 21398049
[TBL] [Abstract][Full Text] [Related]
13. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
[TBL] [Abstract][Full Text] [Related]
14. Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma.
Aref A; Narayan S; Tekyi-Mensah S; Varterasian M; Dan M; Eilender D; Karanes C; al-Katib A
Radiat Oncol Investig; 1999; 7(3):186-91. PubMed ID: 10406061
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
Oguchi M; Ikeda H; Isobe K; Hirota S; Hasegawa M; Nakamura K; Sasai K; Hayabuchi N
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):161-8. PubMed ID: 10924986
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
18. External beam radiation therapy in the treatment of patients with extranodal stage IA non-Hodgkin's lymphoma.
Briggs JH; Algan O; Miller TP; Oleson JR
Am J Clin Oncol; 2002 Feb; 25(1):34-7. PubMed ID: 11823692
[TBL] [Abstract][Full Text] [Related]
19. Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatment.
Pelloski CE; Wilder RB; Ha CS; Hess MA; Cabanillas FF; Cox JD
Radiother Oncol; 2001 May; 59(2):145-51. PubMed ID: 11325442
[TBL] [Abstract][Full Text] [Related]
20. Involved field radiotherapy or chemotherapy in the management of stage I nodal intermediate grade non-Hodgkin's lymphoma.
Jeffery GM; Mead GM; Whitehouse JM; Ryall RD
Br J Cancer; 1991 Nov; 64(5):933-7. PubMed ID: 1931619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
